Wells Fargo & Company Cyma Bay Therapeutics, Inc. Transaction History

Wells Fargo & Company

16 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 09, 2024	BUY	$12.63 - $24.47 $130,328 - $252,505	10,319 Added 50.04%	30,941 $730,000
Q3 2023 Nov 13, 2023	SELL	$10.86 - $17.62 $220,012 - $356,963	-20,259 Reduced 49.56%	20,622 $307,000
Q2 2023 Aug 15, 2023	BUY	$7.47 - $10.95 $300,757 - $440,868	40,262 Added 6504.36%	40,881 $447,000
Q1 2023 May 12, 2023	BUY	$5.88 - $9.59 $482 - $786	82 Added 15.27%	619 $5,000
Q4 2022 Feb 13, 2023	SELL	$3.22 - $6.27 $521 - $1,015	-162 Reduced 23.18%	537 $3,000
Q3 2022 Nov 14, 2022	SELL	$2.77 - $4.25 $27 - $42	-10 Reduced 1.41%	699 $3,000
Q2 2022 Aug 12, 2022	SELL	$1.72 - $3.39 $15,738 - $31,018	-9,150 Reduced 92.81%	709 $3,000
Q1 2022 May 16, 2022	SELL	$2.77 - $3.64 $58,507 - $76,884	-21,122 Reduced 68.18%	9,859 $31,000
Q4 2021 Feb 14, 2022	BUY	$3.23 - $4.6 $86,512 - $123,206	26,784 Added 638.17%	30,981 $105,000
Q3 2021 Nov 15, 2021	SELL	$3.47 - $4.42 $139,240 - $177,361	-40,127 Reduced 90.53%	4,197 $16,000
Q2 2021 Aug 16, 2021	SELL	$3.94 - $4.92 $711,634 - $888,640	-180,618 Reduced 80.3%	44,324 $194,000
Q1 2021 May 13, 2021	BUY	$4.23 - $6.55 $186,801 - $289,254	44,161 Added 24.43%	224,942 $1.02 Million
Q4 2020 Feb 09, 2021	BUY	$5.73 - $9.03 $743,513 - $1.17 Million	129,758 Added 254.31%	180,781 $1.04 Million
Q3 2020 Nov 05, 2020	SELL	$3.32 - $7.24 $43,382 - $94,605	-13,067 Reduced 20.39%	51,023 $369,000
Q2 2020 Aug 13, 2020	BUY	$1.41 - $4.25 $26,482 - $79,823	18,782 Added 41.45%	64,090 $224,000
Q1 2020 May 14, 2020	BUY	$1.25 - $2.02 $56,635 - $91,522	45,308 New	45,308 $67,000

1.82M

Ticker CBAY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 84,677,904
Description
CymaBay Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and providing therapies to treat liver and other chronic diseases. Its lead product candidate is seladelpar (MBX-8025), a selective agonist of peroxisome proliferator activated receptor delta that is in phase III clinical study for the treatments of pri...

Get notified when there are updates to the investment portfolio of Wells Fargo & Company, based on Form 13F filings with the SEC.

Stay updated on Wells Fargo & Company with notifications on news.